pre-IPO PHARMA

COMPANY OVERVIEW

Adastra Pharmaceuticals Inc. is a private clinical-stage oncology company committed to providing responsible solutions to advance patient care in oncology. The Adastra lead clinical candidate, zotiraciclib, is initially being developed for the treatment of glioblastoma multiforme (GBM) and diffuse intrinsic pontine glioma (DIPG), two brain cancers characterized by Myc overexpression. Zotiraciclib is the subject of separate clinical studies in GBM, as well as an upcoming pilot study in DIPG.


LOCATION

  • San Diego, CA, USA
  • Princeton, NJ, USA

  • THERAPEUTIC AREAS

  • Oncology

  • WEBSITE

    https://www.adastrarx.com


    CAREER WEBSITE


    SOCIAL MEDIA


    INVESTORS

    domain-associates morgenthaler-ventures proquest-investments rmi


    PRESS RELEASES


    Jan 14, 2021

    Adastra Pharmaceuticals, Inc. to Present at Inaugural B. Riley Securities' Oncology Investor Conference


    Jan 13, 2021

    Adastra Pharmaceuticals Announces Positive Top-Line Data from Phase 1b Clinical Trial of Zotiraciclib in the Treatment of Recurrent High-grade Gliomas


    Jul 28, 2020

    Adastra Pharmaceuticals to Present at LifeSci Partners' Summer Symposium


    Dec 4, 2019

    Adastra Pharmaceuticals Announces FDA and EMA Orphan Drug Designation Has Been Granted for Zotiraciclib in the Treatment of Glioma


    Sep 4, 2019

    Adastra Pharmaceuticals to Present at the 2019 Janney Healthcare Conference


    For More Press Releases


    Google Analytics Alternative